This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTC:SNTI) announced that as of Wednesday, November 21, 2012, the Company’s common stock will be quoted on the OTC.QB under the ticker symbol SNTI. Quotes for the Company’s common stock can be obtained on the OTC Markets website,
www.otcmarkets.com. The Company plans to continue to be a fully reporting issuer compliant with applicable federal and state regulations.
“Over the last several months ahead of the NYSE MKT imposed deadline, we have been working to maintain our NYSE MKT listing and had established that we needed to raise considerable additional capital to get back in compliance with NYSE MKT listing requirements. Management and the board decided that a highly dilutive or toxic financing at the current time just to maintain the NYSE MKT listing was not in the best interest of our stockholders and that stockholders would be better served by temporarily moving over to OTC,” stated Dr. Leslie J. Browne, President & CEO of Senesco. “Now that we have successfully transferred to OTC we are no longer required to meet the net equity requirement to stay on NYSE MKT, and we are able to use capital that we may raise to build on the previously reported promising results from the ongoing clinical trial and advance the SNS01-T study towards completion.”
Senesco plans to release a corporate update on Monday, November 26
th, 2012, by way of a press release, to describe progress on various aspects of the business.
About Senesco Technologies, Inc.
Senesco, a leader in eIF5A technology, is sponsoring a clinical study to evaluate its lead therapeutic candidate SNS01-T in multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma. SNS01-T targets B-cell cancers and selectively induces apoptosis by modulating eukaryotic translation initiation factor 5A (eIF5A), which is believed to be an important regulator of cell growth and cell death. Accelerating apoptosis may have applications in treating cancer, while delaying apoptosis may have applications in treating certain inflammatory and ischemic diseases. Senesco has already partnered with leading-edge companies engaged in agricultural biotechnology and biofuels development, and is entitled to earn research and development milestones and royalties if its gene-regulating platform technology is incorporated into its partners’ commercialized products.